secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001558370-23-014708
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics announces Roche collaboration for XTX101 in MSS CRC; cash $75.4M
--------------------------------------------------------------------------------

- Entered clinical trial collaboration with Roche; Xilio retains rights to XTX101; eligible for cost-sharing payments.
- Updated XTX101 data: durable partial response 36 wks in NSCLC; no Grade 4/5 AEs at RP2D; no colitis.
- XTX202 cleared 2.8 mg/kg dose, no vascular leak; expects preliminary Phase 1/2 data early Nov 2023 in ≥20 evaluable pts.
- Q2 net loss $19.4M vs $24.6M YoY; cash $75.4M, runway into Q2 2024.
- Promoted Chris Frankenfield to COO; XTX301 safety data expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023014708/0001558370-23-014708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023014708/xlo-20230814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer